Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis

Gastrointestinal Endoscopy

Volumn 59, Issue 6, 2004, Pages 606-613

  Rabenstein, Thomas ^a   Fischer, Bernhard ^b   Wießner, Volkmar ^b   Schmidt, Harald ^b   Radespiel Tröger, Martin ^b   Hochberger, Jürgen ^b   Mühldorfer, Steffen ^b   Nusko, Gerhard ^b   Messmann, Helmut ^b   Schölmerich, Jürgen ^b   Schulz, Hans Joachim ^b   Schönekäs, Herbert ^b   Hahn, Eckhart Gustav ^b   Schneider, Hans Thomas ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CERTOPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; BILE DUCT OBSTRUCTION; BILE DUCT STONE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SPHINCTEROTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREATITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ACUTE DISEASE; AGED; ANTI-INFLAMMATORY AGENTS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOUBLE-BLIND METHOD; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 2342555714     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5107(04)00159-2     Document Type: Article

References (38)

1. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-18.
2. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417-23.
3. Freeman ML, DiSario JA, Nelson DB, Fennerty B, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54:425-34.
4. Loperfido S, Angelini G, Beneditti G, Chilovi F, Costan F, De Berrardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998;48:1-10.
5. Rabenstein T, Schneider HT, Bulling D, Nicklas M, Katalinic A, Hahn EG, et al. Analysis of risk factors of endoscopic sphincterotomy techniques: preliminary results of a prospective study with emphasis on the reduced risk of acute pancreatitis under low-dose anticoagulation. Endoscopy 2000; 32:10-9.
6. Rabenstein T, Roggenbuck S, Framke B, Martus P, Fischer B, Nusko G, et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis following endoscopic retrograde cholangio-pancreatography? Gastrointest Endosc 2002;55:476-83.
7. Rabenstein T, Schneider HT, Hahn EG, Ell C. 25 years of endoscopic sphincterotomy in Erlangen: assessment of experience in the treatment of 3498 patients. Endoscopy 1998; 30(Suppl 2):A194-201.
8. Christoforidis E, Goulimaris I, Kanellos I, Tsalis K, Demetriades C, Betsis D. Post-ERCP pancreatitis and hyperamylasaemia: patients' related and operative risk factors. Endoscopy 2002;34:286-92.
9. Sherman S, Ruffolo TA, Hawes RH, Lehman GA. Complications of endoscopic sphincterotomy: a prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991;101:1068-75.
10. Chen YK, Foliente RL, Santoro MJ, Walter MH, Collen MJ. Endoscopic sphincterotomy-induced pancreatitis: increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction. Am J Gastroenterol 1994; 89:327-33.
11. Fogel EL, Eversman D, Jamidar P, Sherman S, Lehman GA. Sphincter of Oddi dysfunction: pancreatobiliary sphincterotomy with pancreatic stent placement has less pancreatitis than biliary sphincterotomy alone. Endoscopy 2002;34: 280-5.
12. Cotton PB, Lehman GA, Vennes J, Geenen JE, Russel RCG, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-93.
13. Sherman S, Lehman GA. ERCP and endoscopic sphincterotomy induced pancreatitis. Pancreas 1991;6:350-67.
14. Huibregtse K. Complications of endoscopic sphincterotomy and their prevention. N Engl J Med 1996;335:961-3.
15. Tittobello A. Diagnosis and prevention of post-EST pancreatitis. Endoscopy 1997;29:285-7.
16. Haber GB. Prevention of post-ERCP pancreatitis. Gastrointest Endosc 2000;51:1-7.
17. Rabenstein T, Hahn EG. Post-ERCP pancreatitis: new momentum. Endoscopy 2002;34:325-9.
18. Hackert T, Werner J, Gebhard MM, Herfarth C, Klar E. Prevention of post-ERCP pancreatitis by heparin in rats [abstract]. Gastroenterology 2000;118:A426.
19. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Pique JM, et al. Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 2000;47:88-96.
20. Leever R, Robin J, Hoult S, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leukocytes to vascular endothelium in vitro. Br J Pharmacol 2000;129:533-40.
21. König A, Norgard Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. J Clin Invest 1998; 101:877-89.
22. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;82:3253-8.
23. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol 1995;130:1473-82.
24. Panes J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999;126:537-50.
25. Tyrrell DJ, Horne AP, Holme KR, Page CP. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999;46:151-208.
26. Ell C, Rabenstein T, Schneider HT, Ruppert T, Nicklas M, Bulling D. Safety and efficacy of pancreatic sphincterotemy in chronic pancreatitis. Gastrointest Endosc 1998;48:244-9.
27. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford: Blackwell; 1994.
28. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
29. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955;11:375-86.
30. Panes J, Esteve M, Cabre E, Hinojosa J, Andreu M, Sans M, et al. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 2000;119:903-8.
31. Schölmerich J. Immunologic mechanisms in acute pancreatitis. In: Lankisch PG, DiMagno EP, editors. Pancreatic disease. Berlin: Springer-Verlag; 1999. p. 24-35.
32. Deviere J, Le Moine O, Van Laethem JL, Eisendrath P, Ghilain A, Severs N, et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001;120:498-505.
33. Dumot JA, Conwell DL, Zuccaro G, Vargo JJ, Shay SS, Easley KA, et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001;96:2098-102.
34. Rabenstein T, Radespiel-Troeger M, Siebert S, Hochberger J, Muehldorfer S, Nusko G, et al. Post-ERCP pancreatitis: prospective analysis of risk factors. Gastrointest Endosc 2002; 55(Suppl S):T1746.
35. Tarnasky P, Palesch Y, Cunningham JT, Mauldin PD, Cotton PB, Hawes RH. Pancreatic stenting prevents pancreatitis after biliary sphincterotemy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998;115:1518-24.
36. Aizawa T, Ueno N. Stent placement in the pancreatic duct prevents pancreatitis after endoscopic sphincter dilation for removal of bile duct stones. Gastrointest Endosc 2001;54:209-13.
37. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariani A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy: Italian Group. N Engl J Med 1996;335:919-23.
38. Andriulli A, Gioacchino L, Grazia N, Mangia A, Festa V, Gambassi G, et al. Medical treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51:1-7.